fep blue glp 1 coverage 2025 EOC model A Closer Look at 2025
Description
FDA approves Novo Nordisks first oral GLP-1 pill Wegovy for obesity, offering an injection-free option and improving long-term treatment adherence.
Claims alone miss critical insights but integrated real-world data reveals the comprehensive patient journey.
Patients diagnosed with diabetes are initiating GLP-1 treatment more quickly than ever before Since 2021, the average time between a diabetes diagnosis and the initiation of a GLP-1 therapy has decreased by about one month, underscoring how quickly these drugs have moved to the forefront of care
We use a dynamic microsimulation to estimate value-based prices that account for the health benefits, medical savings and productivity gains these treatments provide
22 Essential Vitamins & Minerals
